Clinical trial • Phase III|Phase IV • Respiratory
ROCURONIUM BROMIDE for Respiratory distress
Phase III|Phase IV trial of ROCURONIUM BROMIDE for Respiratory distress.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Respiratory distress
- Trial Stage
- Phase III|Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 26-07-2024
- First CTIS Authorization Date
- 12-09-2024
Trial design
Randomised, open-label, experimental group: combined strategy integrating rocuronium (rocuronium bromide), bag face-mask ventilation before intubation and gum elastic bougie (geb). control group: usual tracheal intubation process. no specific doses or schedules for the comparator arms are specified in the available record. Phase III|Phase IV trial in France.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Experimental group: Combined strategy integrating rocuronium (rocuronium bromide), bag face-mask ventilation before intubation and gum elastic bougie (GEB). Control group: Usual tracheal intubation process. No specific doses or schedules for the comparator arms are specified in the available record.
- Target Sample Size
- 1500
- Trial Duration For Participant
- 28
Eligibility
Recruits 1500 Patients under specific protection measures (pregnant, parturient or nursing women; patients under judicial protection, guardianship/curatorship; deprived of liberty) are explicitly listed as excluded. The trial population is adults (≥18 years). Subject information and informed consent forms for adults are provided (documents: 'L1_SIS and ICF_adults' and 'L1_SIS and ICF_adults_TC'); no assent/minor consent procedures are described because minors are excluded..
- Pregnancy Exclusion
- Patient under specific protection measures: pregnant, parturient or nursing women ; legal protection or deprived of liberty : patient under judicial protection, patient under guardianship/curatorship
- Vulnerable Population
- Patients under specific protection measures (pregnant, parturient or nursing women; patients under judicial protection, guardianship/curatorship; deprived of liberty) are explicitly listed as excluded. The trial population is adults (≥18 years). Subject information and informed consent forms for adults are provided (documents: 'L1_SIS and ICF_adults' and 'L1_SIS and ICF_adults_TC'); no assent/minor consent procedures are described because minors are excluded.
Inclusion criteria
- {"criterion_text":"- Adult (≥ 18 years) patient presenting with vital distress needing an emergency endotracheal intubation , and treated by the participating SMUR"}
- {"criterion_text":"- Patient with all conditions (trauma, dyspnea, coma, overdoses, and shock) except those in cardiac arrest"}
Exclusion criteria
- {"criterion_text":"- Patient presenting of a contraindication to succinylcholine, and/or rocuronium, and/or sugammadex (rocunorium antagonist)"}
- {"criterion_text":"- Patient who have contraindication to bag face mask ventilation before intubation (ongoing emesis, hematemesis, or hemoptysis)"}
- {"criterion_text":"- Patient that are not members of a medical aid scheme (beneficiary or main member)"}
- {"criterion_text":"- Patient under specific protection measures: pregnant, parturient or nursing women ; legal protection or deprived of liberty : patient under judicial protection, patient under guardianship/curatorship"}
Endpoints
Primary endpoints
- {"endpoint_text":"- proportion of patients with severe intubation-related complications occurring during the first hour after intubation. Severe intubation-related complications are: Cardiac arrest. At least one arterial hypotension episode defined by systolic blood pressure<90 mmHg. At least one hypoxemia episode defined by an occurrence of a new episode of oxygen saturation<90%. Severe cardiac arrhythmia: ventricular tachycardia. Pulmonary aspiration. Esophageal intubation. Unintentional extubation.","definition_or_measurement_approach":"Severe intubation-related complications defined as: Cardiac arrest; ≥1 arterial hypotension episode (systolic BP < 90 mmHg); ≥1 hypoxemia episode (new occurrence of oxygen saturation <90%); severe cardiac arrhythmia (ventricular tachycardia); pulmonary aspiration; esophageal intubation; unintentional extubation. Measured as proportion of patients experiencing these events during the first hour after intubation."}
Secondary endpoints
- {"endpoint_text":"- Difficulty of the intubation process: Intubation Difficulty Score: Intubation Difficulty Score > 5 defining difficult intubation.18","definition_or_measurement_approach":"Proportion of patients with Intubation Difficulty Score (IDS) > 5 defining difficult intubation."}
- {"endpoint_text":"- Difficulty of the intubation process: Intubation conditions assessed by the Copenhagen score19: Poor conditions/Good conditions/Excellent conditions","definition_or_measurement_approach":"Intubation conditions assessed using the Copenhagen score categorized as Poor / Good / Excellent."}
- {"endpoint_text":"- Difficulty of the intubation process: Proportion of patients intubated by alternative techniques (stylet, gum elastic bougie, Intubating Laryngeal Mask Airway (ILMA) [e.g., Fastrach], or cricothyrotomy)","definition_or_measurement_approach":"Proportion of patients requiring alternative intubation techniques (stylet, gum elastic bougie, ILMA, or cricothyrotomy)."}
- {"endpoint_text":"- Difficulty of the intubation process: Mean number of intubation attempts","definition_or_measurement_approach":"Mean (average) number of intubation attempts per patient."}
- {"endpoint_text":"- Difficulty of the intubation process: Mean number of intubation failures under direct laryngoscopy","definition_or_measurement_approach":"Mean number of intubation failures when using direct laryngoscopy."}
- {"endpoint_text":"- Out-of hospital care: Mean time of out-of-hospital care (in minutes), defined from time of SMUR arrival on scene to time of hospitalization","definition_or_measurement_approach":"Mean duration (minutes) of out-of-hospital care measured from SMUR arrival on scene to hospital admission."}
- {"endpoint_text":"- Out-of hospital care: Mean total amount of sedative drugs used after intubation","definition_or_measurement_approach":"Mean total quantity of sedative drugs administered after intubation (specific measurement units not provided)."}
- {"endpoint_text":"- Out-of hospital care: Mean total amount of vasopressors used after intubation","definition_or_measurement_approach":"Mean total quantity of vasopressors administered after intubation (specific measurement units not provided)."}
- {"endpoint_text":"- Out-of hospital care: Out-of-hospital mortality, defined as the proportion of patients who died during the out-of-hospital time","definition_or_measurement_approach":"Proportion of patients who died during the out-of-hospital time."}
- {"endpoint_text":"- Mortality at 28 days: The follow-up of patients stopping at hospital admission, the vital status of the patient will be retrieved using the open-access French Register of deceased persons (\"Fichier des personnes décédées\") maintained by INSEE (website: https://deces.matchid.io/search)","definition_or_measurement_approach":"Vital status at 28 days obtained via the French Register of deceased persons (INSEE) to determine 28-day mortality."}
Recruitment
- Planned Sample Size
- 1500
- Recruitment Window Months
- 44
- Consent Approach
- Informed consent handled using adult subject information and informed consent forms (documents listed: 'L1_SIS and ICF_adults' and 'L1_SIS and ICF_adults_TC'). Participants are adults (≥18) who provide consent; no assent or minor-specific consent procedures are described in the available records.
Methods
- Enrolment occurs via participating SMUR (emergency medical service) teams during out-of-hospital emergency tracheal intubations in France; patients are identified and enrolled at the point of care by treating SMUR clinicians.
Geography
- Total Number Of Sites
- 19
- Total Number Of Participants
- 1500
France
- Earliest CTIS Part Ii Submission Date
- 31-07-2024
- Latest Decision Or Authorization Date
- 03-09-2025
- Processing Time Days
- 399
- Number Of Sites
- 19
- Number Of Participants
- 1500
Sites
- Site Name
- Centre Hospitalier Universitaire Grenoble Alpes
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Guillaume DEBATY
- Principal Investigator Email
- gdebaty@chu-grenoble.fr
- Contact Person Name
- Guillaume DEBATY
- Contact Person Email
- gdebaty@chu-grenoble.fr
- Site Name
- Hopital NOVO
- Department Name
- SMUR Urgences adultes - CH René Dubois Pontoise
- Principal Investigator Name
- Agnès RICARD-HIBON
- Principal Investigator Email
- agnes.ricard-hibon@ght-novo.fr
- Contact Person Name
- Agnès RICARD-HIBON
- Contact Person Email
- agnes.ricard-hibon@ght-novo.fr
- Site Name
- Groupement Hospitalier Eaubonne Montmorency Simone Veil
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Laure GUILLOUX
- Principal Investigator Email
- laureguilloux@hotmail.fr
- Contact Person Name
- Laure GUILLOUX
- Contact Person Email
- laureguilloux@hotmail.fr
- Site Name
- Centre Hospitalier Universitaire De La Reunion
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Adrien MARTEAU
- Principal Investigator Email
- adrien.marteau@chu-reunion.fr
- Contact Person Name
- Adrien MARTEAU
- Contact Person Email
- adrien.marteau@chu-reunion.fr
- Site Name
- Assistance Publique Hopitaux De Paris (Creteil)
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Charlotte CHOLLET-XEMARD
- Principal Investigator Email
- charlotte.chollet@aphp.fr
- Contact Person Name
- Charlotte CHOLLET-XEMARD
- Contact Person Email
- charlotte.chollet@aphp.fr
- Site Name
- Assistance Publique Hopitaux De Paris (Garches)
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Armelle SEVERIN
- Principal Investigator Email
- armelle.severin@aphp.fr
- Contact Person Name
- Armelle SEVERIN
- Contact Person Email
- armelle.severin@aphp.fr
- Site Name
- Assistance Publique Hopitaux De Paris (2 Rue Ambroise Pare)
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Xavier Dominique EYER
- Principal Investigator Email
- xavier.eyer@aphp.fr
- Contact Person Name
- Xavier Dominique EYER
- Contact Person Email
- xavier.eyer@aphp.fr
- Site Name
- Assistance Publique Hopitaux De Paris (43 Boulevard De L Hopital)
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Patrick ECOLLAN
- Principal Investigator Email
- patrick.ecollan@aphp.fr
- Contact Person Name
- Patrick ECOLLAN
- Contact Person Email
- patrick.ecollan@aphp.fr
- Site Name
- Centre Hospitalier Universitaire De Bordeaux
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Xavier COMBES
- Principal Investigator Email
- xavier.combes@chu-bordeaux.fr
- Contact Person Name
- Xavier COMBES
- Contact Person Email
- xavier.combes@chu-bordeaux.fr
- Site Name
- Hopital NOVO (Pontoise site)
- Department Name
- SMUR Urgences adultes - Site Beaumont
- Principal Investigator Name
- Agnès RICARD-HIBON
- Principal Investigator Email
- agnes.ricard-hibon@ght-novo.fr
- Contact Person Name
- Agnès RICARD-HIBON
- Contact Person Email
- agnes.ricard-hibon@ght-novo.fr
- Site Name
- Assistance Publique Hopitaux De Paris (Bobigny)
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Frédéric LAPOSTOLLE
- Principal Investigator Email
- frederic.lapostolle@aphp.fr
- Contact Person Name
- Frédéric LAPOSTOLLE
- Contact Person Email
- frederic.lapostolle@aphp.fr
- Site Name
- Centre Hospitalier Universitaire D'Angers
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Dominique SAVARY
- Principal Investigator Email
- dominique.savary@chu-angers.fr
- Contact Person Name
- Dominique SAVARY
- Contact Person Email
- dominique.savary@chu-angers.fr
- Site Name
- Centre Hospitalier Universitaire De Poitiers
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Nicolas MARJANOVIC
- Principal Investigator Email
- patrick.ecollan@aphp.fr
- Contact Person Name
- Nicolas MARJANOVIC
- Contact Person Email
- patrick.ecollan@aphp.fr
- Site Name
- Assistance Publique Hopitaux De Paris (149 Rue De Sevres)
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Benoît VIVIEN
- Principal Investigator Email
- benoit.vivien@aphp.fr
- Contact Person Name
- Benoît VIVIEN
- Contact Person Email
- benoit.vivien@aphp.fr
- Site Name
- Centre Hospitalier Universitaire De Montpellier
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Xavier BOBBIA
- Principal Investigator Email
- xavier.bobbia@chu-montpellier.fr
- Contact Person Name
- Xavier BOBBIA
- Contact Person Email
- xavier.bobbia@chu-montpellier.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Marine PAUPE
- Principal Investigator Email
- marine.paupe@chu-lyon.fr
- Contact Person Name
- Marine PAUPE
- Contact Person Email
- marine.paupe@chu-lyon.fr
- Site Name
- Centre Hospitalier Universitaire De Toulouse
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Bertrand GUIHARD
- Principal Investigator Email
- guihard.b@chu-toulouse.fr
- Contact Person Name
- Bertrand GUIHARD
- Contact Person Email
- guihard.b@chu-toulouse.fr
- Site Name
- Groupe Hospitalier Du Sud Ile De France
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Yousra GUETARI
- Principal Investigator Email
- yousra.guetari@ghsif.fr
- Contact Person Name
- Yousra GUETARI
- Contact Person Email
- yousra.guetari@ghsif.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- SMUR Urgences adultes
- Principal Investigator Name
- Quentin LE BASTARD
- Principal Investigator Email
- quentin.lebastard@chu-nantes.fr
- Contact Person Name
- Quentin LE BASTARD
- Contact Person Email
- quentin.lebastard@chu-nantes.fr
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire De Bordeaux
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- ROCURONIUM VIATRIS 10 mg/mL, solution injectable/pour perfusion
- Active Substance
- ROCURONIUM BROMIDE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS USE
- Route
- INTRAVENOUS USE
- Authorisation Status
- Authorised
- Maximum Dose
- 10 mg/ml
- Investigational Product Name
- CELOCURINE 50 mg/ml, solution injectable
- Active Substance
- SUXAMETHONIUM CHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS USE
- Route
- INTRAVENOUS USE
- Authorisation Status
- Authorised
- Maximum Dose
- 1 mg/kg
- Investigational Product Name
- SUGAMMADEX JUTA PHARMA 100 mg/mL, solution injectable
- Active Substance
- SUGAMMADEX
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS USE
- Route
- INTRAVENOUS USE
- Authorisation Status
- Authorised
- Maximum Dose
- 100 mg/ml
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- phospholipid fraction, bovine lung for Idiopathic pulmonary fibrosis
- Allogeneic bone marrow-derived mesenchymal adult stromal cells, ex-vivo expanded for Chronic lung allograft dysfunction (CLAD) | Bronchiolitis obliterans syndrome (BOS) in lung transplant recipients
- IVX-121; HUMAN METAPNEUMOVIRUS, VIRUS-LIKE PROTEIN for Respiratory syncytial virus infection | Human metapneumovirus infection
- Lyophilized bacterial lysates of: Haemophilus influenzae, Streptococcus (Diplococcus) pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Moraxella (Branhamella/Neisseria) catarrhalis (OM-85) for Respiratory tract infections with wheezing lower respiratory illness
- Roginolisib for Advanced non-squamous non-small cell lung cancer